Journal: Experimental Biology and Medicine

Article Title: Poliovirus receptor (PVR) expression as a predictor of relapse in colorectal cancer: bioinformatics and virtual screening

doi: 10.3389/ebm.2026.10745

Figure Lengend Snippet: Molecular docking representations of the active site of the poliovirus receptor (PVR/CD155) interacting with (A) ZINC000096115646, (B) ZINC001848443492, (C) ZINC000524729757, and (D) TIGIT, highlighting key binding residues and interactions. The yellow ribbons depict the PVR structure, while green structures represent the ligands or TIGIT, with specific amino acid residues (e.g., Ser132, Glu70, His187) and hydrogen bonds (blue dashed lines) illustrating the binding interfaces.

Article Snippet: The Molecular Dynamics (MD) simulation results, as depicted in the provided Root Mean Square Deviation (RMSD) plot over a 100 ns timeframe , compare the structural stability of the poliovirus receptor (PVR/CD155) in its apo form with its complexes bound to three compounds: ZINC000096115646, ZINC001848443492, and ZINC000524729757.

Techniques: Binding Assay

Journal: Experimental Biology and Medicine

Article Title: Poliovirus receptor (PVR) expression as a predictor of relapse in colorectal cancer: bioinformatics and virtual screening

doi: 10.3389/ebm.2026.10745

Figure Lengend Snippet: Molecular Dynamics simulation analyses of the poliovirus receptor (PVR/CD155) over 100 ns. (A) RMSD (Root Mean Square Deviation) plots comparing the structural stability of PVR in its apo form (black) and when bound to ZINC000096115646 (blue), ZINC001848443492 (red), and ZINC000524729757 (green). (B) RMSF (Root Mean Square Fluctuation) plots illustrating per-residue flexibility for the apo-protein (black) and complexes with ZINC000524729757 (red), ZINC001848443492 (blue), and ZINC000096115646 (green). (C) Radius of gyration (Rg) plots assessing compactness for the apo-protein (black) and complexes with ZINC000524729757 (red), ZINC000070708573 (blue), and ZINC000096115646 (green). (D) SASA (Solvent Accessible Surface Area) plots indicating solvent exposure for the apo-protein (black) and complexes with ZINC000524729757 (red), ZINC000096115646 (green), and ZINC001848443492 (blue).

Article Snippet: The Molecular Dynamics (MD) simulation results, as depicted in the provided Root Mean Square Deviation (RMSD) plot over a 100 ns timeframe , compare the structural stability of the poliovirus receptor (PVR/CD155) in its apo form with its complexes bound to three compounds: ZINC000096115646, ZINC001848443492, and ZINC000524729757.

Techniques: Residue, Solvent

Journal: Frontiers in Immunology

Article Title: Enhancing anti-tumor immunity through co-blocking PD-L1 and TIGIT by facilitating tumor-directed responses and additional VEGF inhibition

doi: 10.3389/fimmu.2025.1746155

Figure Lengend Snippet: Pattern of expression of PD-L1 and CD155 (PVR) and its correlation to blocking and immune landscape. (A) FACS plots show expression pattern of PD-L1 and CD155 by HT-1080 cells. (B) CTV-labelled PBMCs were cultured with mitomycin-treated HT-1080 cells in 96-well plates with indicated Abs at equal molar concentrations. Histograms show the numbers of proliferated cells under stimulated conditions. **** p < 0.0001 by one-way ANOVA multiple-comparisons test. (C–H). High-Content Analysis of human lung adenocarcinoma microenvironment. Multiplex immunofluorescence and quantitative analysis were used to profile the tumor (PanCK + ) and stromal (PanCK - ) compartments. (C) Representative High-Content analysis images illustrating the immune landscape in adenocarcinoma tissue. (D) Quantification of the percentage of cells expressing PD-L1 within the PanCK + tumor and PanCK - stromal compartments. Lines connect paired tumor and stroma samples from the same patient. The mean difference between compartments is plotted on the right axis for each graph. PD-L1 expression was then further expressed as Tumor Proportion Score (TPS), calculated as the ratio of PanCK + PD-L1 + cells to PanCK + tumor cells, and a Combined Positive Score (CPS), calculated as the ratio of all PD-L1 + cells to PanCK + tumor cells. (E) Quantification of the percentage of cells expressing CD155 within the PanCK + tumor and PanCK - stromal compartments. Lines connect paired tumor and stroma samples from the same patient. The mean difference between compartments is plotted on the right axis for each graph. (F) Co-expression analysis of PD-L1 and CD155 on PanCK + tumor cells. Each dot represents a patient sample. Dashed lines indicate the median density of the cohort for each marker, stratifying tumors into four subsets. (G) Graphs show Frequencies of CD4 + and CD8 + T cells, calculated as a percentage of total cells within the tissue; Frequencies of PD-1, TIGIT, and CD226 expression on CD4 + and CD8 + T cells, shown as a percentage of the parent T-cell population; and Linear regression analysis showing a significant positive correlation between the density (cells/mm 2 ) of TIGIT + and CD226 + cells within the CD4 + (left) and CD8 + (right) T cell populations. R 2 and P values are shown. (H) Correlation analysis between the density of total PD-L1 + cells (left) or total CD155 + cells (right) and the density of CD4 + (red line) or CD8 + (blue line) T cells.

Article Snippet: Cells were activated with PHA-M (Yeasen, Cat#: 40110ES08, lot: P2107890; 0.95 μg/mL final concentration) and co-treated with soluble CD155 (Sino Biological, Cat#10109-H02H; 8 μg/mL final concentration).

Techniques: Expressing, Blocking Assay, Cell Culture, High Content Screening, Multiplex Assay, Immunofluorescence, Marker